Corperate Fact Sheet

SemiAlloGen is a privately held biopharmaceutical company developing immunotherapeutic products for the treatment of cancer and Alzheimer’s disease (AD) the most common form of senile dementia. The Company was formed in Charleston and incorporated in Delaware for commercial development of research performed at the Medical University of South Carolina (MUSC) on a proprietary technology to produce therapeutic, adjuvant, and preventive vaccines for the treatment of cancer and AD. This vaccine consists of cell hybrids resulting from the fusion of a unique, genetically-altered human cell line from our laboratory (called Fo1-12) with cancer cells or white blood cells (WBC) derived from the patient. We believe that these hybrid vaccines will direct a powerful cell-mediated immune response to destroy cancer or cells producing excess amounts of the ß amyloid peptide (A ß), the causative agent of AD. We have successfully completed a phase I trial (allowed by the Food and Drug Administration – FDA) on patients with metastatic melanoma in which safety of the vaccine was demonstrated. We also discovered that our patented Fo1012 cell line expressed high levels of carcino-embryonic antigen (CEA), a major adenocarcinoma-associated tumor antigen. The FDA quickly agreed to expand the clinical studies to include a phase I trial for patients with metastatic adenocarcinomas, including colorectal, pancreatic, and breast cancers. This clinical trial, which involved the formulation of the hybrid vaccine with the immunostimulating cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), was also successfully completed